IMM-101
Title: A trial comparing gemcitabine with and without IMM-101
in advanced pancreatic cancer
Full title: A randomised, open-label,
proof-of-concept, phase II trial comparing gemcitabine with and
without IMM-101 in advanced pancreatic cancer
Phase II Trial
Why is this trial being carried out?
Gemcitabine is a chemotherapy drug that is often used to treat
pancreatic cancer. It is sometimes combined with other drugs to try
to improve treatment.
This trial is looking at whether combining gemcitabine with
another drug called IMM-101 is a more effective treatment than
gemcitabine alone. IMM-101 is a form of mycobacterial
immunotherapy, a type of treatment that aims to stimulate the
immune system.
Who is the trial suitable for?
The trial is suitable for patients with pancreatic cancer that
cannot be removed with surgery or that has spread to another part
of the body, and who have not have previous chemotherapy treatment.
Your doctor(s) will explain these and any other requirements to
join the trial.
Trial centres
The trial is recruiting in Bradford, Airedale, London and
Peterborough.
Recruitment start date: July
2011
Recruitment end date: July 2012
For more information
ClinicalTrials.gov